Immutep Limited, a Sydney-based biotechnology company, is advancing cutting-edge research and development efforts in the pharmaceutical industry. With a focus on developing immunotherapeutic products to address cancer and autoimmune diseases, Immutep has rapidly emerged as a leader in the field. At the forefront of its product pipeline is eftilagimod alpha, a recombinant protein that is currently in Phase IIb clinical trials as a chemo-immunotherapy combination for metastatic breast cancer. Beyond this, the company is also advancing several promising product candidates - such as the TACTI-002, TACTI-003, INSIGHT-003, and INSIGHT-005 - all of which are undergoing clinical trials for the treatment of solid tumors, head and neck squamous cell carcinoma, and non-small cell lung cancer. Through partnerships with industry heavyweights like GlaxoSmithKline, Merck, and Novartis, Immutep continues to accelerate its product development efforts and position itself for long-term success in an evolving global marketplace.
Immutep Limited's ticker is IMMP
The company's shares trade on the NASDAQ stock exchange
They are based in Sydney, Australia
There are 11-50 employees working at Immutep Limited
It is https://www.immutep.com/
Immutep Limited is in the Healthcare sector
Immutep Limited is in the Biotechnology industry
The following five companies are Immutep Limited's industry peers: